Switching From DPP-4 Inhibitors to Oral Semaglutide Improves Blood Sugar and Weight in Japanese Diabetic Patients
Switching from DPP-4 inhibitors to oral semaglutide reduced HbA1c from 7.8% to 7.0% and decreased body weight in 68 Japanese type 2 diabetes patients, with 95.6% improving in at least one measure.
Quick Facts
What This Study Found
Switching from DPP-4i to oral semaglutide reduced mean HbA1c from 7.8% to 7.0% (P significant) and decreased body weight (P significant). 95.6% improved in either HbA1c or weight. Greater HbA1c reduction correlated with greater weight loss (r=0.480, P<0.001). 20% discontinued within 6 months.
Key Numbers
68 Japanese patients were studied after switching from DPP-4 inhibitors to oral semaglutide, with improvements in both HbA1c and body weight.
How They Did This
Single-center retrospective study of 68 Japanese T2D patients switched from DPP-4 inhibitors to oral semaglutide for ≥6 months without changes to other oral hypoglycemics. Outcomes: HbA1c and body weight changes.
Why This Research Matters
DPP-4 inhibitors are the backbone of Japanese diabetes treatment but often provide insufficient control. This study shows oral semaglutide can be a practical step-up that improves both blood sugar and weight without requiring injections.
The Bigger Picture
The shift from DPP-4 inhibitors to GLP-1 agonists is accelerating globally. Oral semaglutide bridges the gap by offering GLP-1-class benefits without injections, which is particularly relevant in Japan where DPP-4 inhibitors dominate and injection resistance is common.
What This Study Doesn't Tell Us
Retrospective, single-center, no control group. Cannot separate drug switch effect from regression to mean. 20% dropout introduces survival bias. No long-term follow-up beyond 6 months. Non-obese older patients had highest discontinuation, suggesting limited utility in this subgroup.
Questions This Raises
- ?Could slower dose titration reduce the 20% dropout rate seen with oral semaglutide?
- ?Is the benefit of switching primarily from semaglutide's greater GLP-1 receptor agonism, or from a different pharmacological mechanism?
- ?Would patients who discontinued oral semaglutide tolerate injectable semaglutide better?
Trust & Context
- Key Stat:
- 7.8% → 7.0% HbA1c Mean HbA1c dropped 0.8 percentage points after switching from DPP-4 inhibitor to oral semaglutide in 68 Japanese patients
- Evidence Grade:
- Moderate evidence — real-world retrospective study with meaningful sample size but no control group and notable dropout rate.
- Study Age:
- Published in 2024, reflecting current DPP-4i to oral semaglutide switching patterns in Japanese clinical practice.
- Original Title:
- Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.
- Published In:
- Diabetology international, 15(3), 569-576 (2024)
- Authors:
- Yoneda, Chihiro, Kobayashi, Junji, Kuribayashi, Nobuichi
- Database ID:
- RPEP-09607
Evidence Hierarchy
Frequently Asked Questions
Why switch from a DPP-4 inhibitor to oral semaglutide?
DPP-4 inhibitors are effective but often don't provide enough blood sugar control or weight loss on their own. Oral semaglutide is a more potent option in the same GLP-1 pathway that can improve both measures without requiring injections.
Who might not tolerate the switch to oral semaglutide?
The study found that older, non-obese patients had the highest discontinuation rate, mainly due to gastrointestinal side effects. These patients may benefit from slower dose titration or may need to try injectable semaglutide instead.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09607APA
Yoneda, Chihiro; Kobayashi, Junji; Kuribayashi, Nobuichi. (2024). Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.. Diabetology international, 15(3), 569-576. https://doi.org/10.1007/s13340-024-00734-5
MLA
Yoneda, Chihiro, et al. "Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.." Diabetology international, 2024. https://doi.org/10.1007/s13340-024-00734-5
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of switching from a dipeptidyl peptidase..." RPEP-09607. Retrieved from https://rethinkpeptides.com/research/yoneda-2024-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.